GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » Debt-to-EBITDA

Core One Labs (XCNQ:COOL) Debt-to-EBITDA : -0.08 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Core One Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.25 Mil. Core One Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Core One Labs's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-3.33 Mil. Core One Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Core One Labs's Debt-to-EBITDA or its related term are showing as below:

XCNQ:COOL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.6   Med: -0.05   Max: 0
Current: -0.12

XCNQ:COOL's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs XCNQ:COOL: -0.12

Core One Labs Debt-to-EBITDA Historical Data

The historical data trend for Core One Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs Debt-to-EBITDA Chart

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.06 -0.60 -0.01 -

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.28 -0.06 - -0.06 -0.08

Competitive Comparison of Core One Labs's Debt-to-EBITDA

For the Biotechnology subindustry, Core One Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Core One Labs's Debt-to-EBITDA falls into.



Core One Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Core One Labs's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.03 + 0) / -36.994
=-0.00

Core One Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.25 + 0) / -3.332
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Core One Labs  (XCNQ:COOL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Core One Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Core One Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs (XCNQ:COOL) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.